LGND - Novan submits NDA for berdazimer gel for viral skin infection

• Novan ( NASDAQ: NOVN ) has submitted a New Drug Application to the US FDA for berdazimer gel for the topical treatment of viral skin infection molluscum contagiosum.
• The submission is the first for the company.
• The application is supported by data from a phase 3 trial that showed highly statistically significant improvement in the primary clinical endpoint.
• Novan is down 13% in Friday morning trading.
• Novan ( NOVN ) is partnered with Ligand Pharmaceuticals ( NASDAQ: LGND ) on berdazimer.
• Seeking Alpha Quant Rating views Novan ( NOVN ) as a hold with strong marks for growth and revisions .

For further details see: